ArticleVaccine2011
Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.
Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes.PLoS neglected tropical diseases · 2012Pooled it
- An outer membrane vesicle vaccine prevents lung pathology in a macaque model of pneumonic melioidosis.Nature communications · 2025Article
- LVS ΔmBio · 2024Article
- Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia.Cancer immunology, immunotherapy : CII · 2023Article
- Nanomedicine: New Frontiers in Fighting Microbial Infections.Nanomaterials (Basel, Switzerland) · 2023Review
- Evaluation of two different vaccine platforms for immunization against melioidosis and glanders.Frontiers in microbiology · 2022Article
- Recent Progress inPathogens (Basel, Switzerland) · 2021Review
- Current Advances inCells · 2020Review
- Improvements to the live-attenuated Newcastle disease virus vaccine using CarbopolVeterinary world · 2020Article
- Article
- Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs.BMC veterinary research · 2019Article
- Novel multi-component vaccine approaches for Burkholderia pseudomallei.Clinical and experimental immunology · 2019Review
- Activation of upper respiratory tract mucosal innate immune responses in cats by liposomal toll-like receptor ligand complexes delivered topically.Journal of veterinary internal medicine · 2019Article
- Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.Frontiers in immunology · 2018Review
- Cationic Liposome-Oligonucleotide Complex as an Alternative Adjuvant for Polyclonal Antibody Production in New Zealand White Rabbits (Comparative medicine · 2017Article
- Vaccines for the Prevention of Melioidosis and Glanders.Current tropical medicine reports · 2017Article
- Article
- The immunological enhancement activity of propolis flavonoids liposome in vitro and in vivo.Evidence-based complementary and alternative medicine : eCAM · 2014Article
- Development of Burkholderia mallei and pseudomallei vaccines.Frontiers in cellular and infection microbiology · 2013Review
- Burkholderia vaccines: are we moving forward?Frontiers in cellular and infection microbiology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Development of effective new mucosal vaccine adjuvants has become a priority with the increase in emerging viral and bacterial pathogens. We previously reported that cationic liposomes complexed with non-coding plasmid DNA (CLDC) were effective parenteral vaccine adjuvants. However, little is known regarding the ability of liposome-nucleic acid complexes to function as mucosal vaccine adjuvants, or the nature of the mucosal immune responses elicited by mucosal liposome-nucleic acid adjuvants. To address these questions, antibody and T cell responses were assessed in mice following intranasal immunization with CLDC-adjuvanted vaccines. The effects of CLDC adjuvant on antigen uptake, trafficking, and cytokine responses in the airways and draining lymph nodes were also assessed. We found that mucosal immunization with CLDC-adjuvanted vaccines effectively generated potent mucosal IgA antibody responses, as well as systemic IgG responses. Notably, mucosal immunization with CLDC adjuvant was very effective in generating strong and sustained antigen-specific CD8(+) T cell responses in the airways of mice. Mucosal administration of CLDC vaccines also induced efficient uptake of antigen by DCs within the mediastinal lymph nodes. Finally, a killed bacterial vaccine adjuvanted with CLDC induced significant protection from lethal pulmonary challenge with Burkholderia pseudomallei. These findings suggest that liposome-nucleic acid adjuvants represent a promising new class of mucosal adjuvants for non-replicating vaccines, with notable efficiency at eliciting both humoral and cellular immune responses following intranasal administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.